ICD involves the release of damage-associated molecular patterns (DAMPs) and tumor-associated antigens (Inoue and Tani, 2014), which can promote DC maturation, enhance antigen cross-presentation to CD8+ T cells, and ultimately stimulate adaptive anti-tumor immunity. Here, CD8A is linked to neoplasm.